Novo Nordisk

Novo Nordisk has such a blockbuster with Wegovy and Ozempic, its market cap has matched the GDP of its home country Denmark. It’s taking in so many dollars, it has affected the exchange rate of the Danish Krone to the Euro. The multinational pharmaceutical company with production facilities in nine countries employs 55,000 worldwide.

While most known for diabetes medications, Novo Nordisk also manufactures and markets pharmaceutical products related to hormone therapy, hemophilia and growth disorders.

For more on the business and cultural impact of new weight loss drugs, see our special series The Obesity Revolution.

Latest

Health Elaine Chen

All Coverage

Pharma Elaine Chen

Latest

STAT Plus: Despite new Wegovy coverage, Medicare patients may face high drug costs and other hurdles

STAT Plus: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label

STAT Plus: Novo Nordisk’s obesity pill bests Wegovy in early trial

STAT Plus: A ‘vaccine-like’ version of Wegovy is on the drawing board at Novo Nordisk

STAT Plus: Novo’s Catalent deal is great for GLP-1s. But what about drug manufacturing?

STAT Plus: As supply crunch starts to ease, Novo Nordisk to offer more doses of obesity drug Wegovy to U.S. patients

STAT Plus: Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs

STAT Plus: Here are the best biopharma CEOs of 2023

All Coverage

STAT Plus: Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation

STAT Plus: Wegovy cuts risk of heart attacks in milestone cardiovascular trial

STAT Plus: Senator floats new models to manage costs of weight loss drugs like Ozempic

STAT Plus: Why doesn’t everyone lose weight on Ozempic-type drugs? Researchers look for genetic clues

STAT Plus: The Ozempic panic: Why a market frenzy over new weight loss drugs defies logic

STAT Plus: Our expensive obesity drugs are worth it, Novo Nordisk and Eli Lilly argue in raft of studies

STAT Plus: How one scientist’s determination made Novo Nordisk an obesity-drug powerhouse

STAT Plus: New obesity drugs are in the works trying to out-blockbuster Wegovy and Mounjaro

Biotech execs vie for a share of obesity drug boom: ‘It’s the early innings’

STAT Plus: Weight loss drug Wegovy improves function in people with common type of heart failure

STAT Plus: What to know about concerns raised by compounded versions of Novo Nordisk’s Wegovy

Listen: Your guide to Wegovy’s blockbuster heart study

STAT Plus: Novo acquires Inversago for up to $1 billion, spotlighting troubled weight loss approach

STAT Plus: Novo Nordisk celebrates landmark Wegovy study, even as supply issues persist

STAT Plus: Wegovy’s successful heart trial raises a vital question about weight loss

STAT Plus: Wegovy cardiovascular study has doctors seeing new possibilities in weight loss drug

STAT Plus: Novo’s obesity drug Wegovy lowers cardiovascular risk by 20%, landmark trial finds

STAT Plus: Major pharma companies call on their suppliers to reduce carbon footprints

STAT Plus: How the new weight loss drugs could upend our understanding of craving, desire, and addiction

STAT Plus: What to know about this summer’s landmark Wegovy heart health study

STAT Plus: Novo Nordisk bought prescribers over 450,000 meals and snacks to promote drugs like Ozempic